Cancer Genetics, Icon Partner
News Jul 08, 2015
The partners will provide services from complex oncology genomic testing to core central laboratory analysis, project and data management, and sample logistics on a global basis. They will leverage Cancer Genetics' expertise in genomics and other technologies focused on cancer and Icon's know-how in strategic development and management, as well as the analysis of lab data from large-scale clinical programs.
The partnership is focused on providing a "comprehensive, integrated, and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV," they said in a statement.
Financial and other terms of the deal were not disclosed.
"This partnership will satisfy the enormous need among biotech and pharmaceutical companies for more efficient and comprehensive testing solutions by integrating [Cancer Genetics'] specialized, genomic testing [into] Icon's laboratory solutions," Cancer Genetics CEO Panna Sharma said.
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Detecting Heart Damage Long Before Parkinson's Symptoms AppearNews
Mapping inflammation in the heart before diagnosis of Parkinson's disease: a new tool for tracking treatment efficacyREAD MORE
3rd International Conference on Diagnostic Microbiology and Infectious Diseases
Sep 24 - Sep 25, 2018
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019